Symposium hosted by Eric S. Winer, MD, and Grzegorz S. Nowakowski, MD
Updated data for 10 evaluable patients in
Curis's PCNSL study
Experts will present at the virtual meeting,
free and open to the public, on September
26, 2024
LEXINGTON, Mass., Sept. 23,
2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a
biotechnology company focused on the development of emavusertib
(CA-4948), an orally available, small molecule IRAK4 inhibitor,
today announced the 3rd Annual Symposium on IRAK4 in
Cancer taking place virtually on September
26, 9:00 AM-1:00 PM E.T.
Hosted by Dr. Eric S. Winer
(Dana-Farber Cancer Institute) and Dr. Grzegorz S. Nowakowski (Mayo Clinic
Comprehensive Cancer Center), this symposium will focus on IRAK4,
an emerging target in the treatment of hematologic malignancies and
solid tumors. Experts will discuss the promise of IRAK4 inhibition
in cancer, including current clinical studies of emavusertib and
opportunities for future development.
Symposium presentations will include updated data for 10
evaluable R/R PCNSL patients as of the July
10, 2024 cutoff date. The Company continues to enroll
patients in the PCNSL study and is on track to enroll 15-20
patients by year-end.
"As the leader in IRAK4 inhibition in oncology with emavusertib,
we are honored to provide a forum for discussing the biology of the
IRAK4 pathway and IRAK4 inhibition in the research and development
of therapies to benefit patients living with cancer," said
James Dentzer, President, and Chief
Executive Officer of Curis.
Symposium co-chairs:
- Eric Winer, MD, Clinical
Director and Adult Leukemia Institute Physician, Dana-Farber Cancer
Institute; Assistant Professor of Medicine, Harvard Medical School
- Grzegorz Nowakowski, MD,
Professor of Oncology and Medicine, Division of Hematology, Deputy
Director of Mayo Clinic Comprehensive Cancer Center for Clinical
Research and Vice-Chair of Division of Hematology
Joining our hosts will be the following speakers and
participants:
- Bently Doonan, MD,
Assistant Professor, Division of Hematology and Oncology,
University of Florida College of
Medicine
- Andrés Ferreri, MD, Contract Professor of Oncology,
University Vita-Salute San Raffaele; Head of the Lymphoma Unit,
I.R.C.C.S. Ospedale San Raffaele
- Klaus Metzeler, MD, Professional of Translational
Hematology, University of Leipzig
- Guillermo Garcia-Manero,
MD, Professor, Chief of Section of Myelodysplastic Syndromes,
Deputy Chair of Translational Research and Fellowship Program
Director Department of Leukemia, Division of Cancer Medicine, The
University of Texas MD Anderson Cancer
Center
- Marina Konopleva, MD,
PhD, Professor of the Department of Oncology, Professor of the
Department of Molecular Pharmacology, and Miriam Mandel Faculty
Scholar in Cancer Research, Albert Einstein
College of Medicine
- Kian Lim, MD, PhD,
Associate Professor, Department of Medicine, Division of Oncology,
Washington University School of
Medicine in St. Louis
- Lakshmi Nayak, MD, Director of the Center for CNS
Lymphoma Dana‑Farber Cancer Institute; Associate Professor of
Neurology, Harvard Medical School
- Han Tun, MD,
Hematologist, Internist, Oncologist, Departments of Hematology and
Mayo Clinic Comprehensive Cancer Center
To learn more about this free-to-attend symposium and register,
please visit https://cvent.me/kDaoDK
About Curis, Inc.
Curis is a biotechnology company focused on the development of
emavusertib, an orally available, small molecule IRAK4 inhibitor.
Emavusertib is currently undergoing testing in the Phase 1/2
TakeAim Lymphoma study (CA-4948-101) in patients with
relapsed/refractory primary central nervous system lymphoma (PCNSL)
in combination with the BTK inhibitor ibrutinib, as a monotherapy
in the Phase 1/2 TakeAim Leukemia study (CA-4948-102) in patients
with relapsed/refractory acute myeloid leukemia (AML) and
relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with
either a FLT3 mutation or a splicing factor mutation (U2AF1 or
SF3B2), and as a frontline combination therapy with azacitidine and
venetoclax in patents with AML (CA-4948-104). Emavusertib has
received Orphan Drug Designation from the U.S. Food and Drug
Administration for the treatment of AML and MDS and from the
European Commission for the treatment of PCNSL. Curis, through its
2015 collaboration with Aurigene, has the exclusive license to
emavusertib (CA-4948). Curis licensed its rights to Erivedge® to
Genentech, a member of the Roche Group, under which they are
commercializing Erivedge® for the treatment of advanced basal cell
carcinoma. For more information, visit Curis's website at
www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-announces-the-3rd-annual-symposium-on-irak4-in-cancer-302254943.html
SOURCE Curis, Inc.